EGFR and neoplasm: Vaccination with the DC, pulsed with recombinant glutathione-S-transferase (GST)-EGFR fusion protein, has been shown to induce a significant anti-tumor immune response against HNSCC, both in vitro and in vivo, in a mice model [126].